Platelet-rich plasma on female androgenetic alopecia: Tested on 10 patients.


Journal

Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964

Informations de publication

Date de publication:
Feb 2019
Historique:
accepted: 19 03 2018
pubmed: 1 5 2018
medline: 28 5 2019
entrez: 1 5 2018
Statut: ppublish

Résumé

Recently, platelet-rich plasma (PRP) injection has been proposed as a potential adjuvant therapy to treat androgenetic alopecia. Investigate the efficacy, tolerability, and clinical improvement of PRP for the treatment of female AGA. A total of 10 female patients affected by AGA and not responding to treatment with minoxidil and/or oral antiandrogens were enrolled. The clinical improvement was evaluated by pull test, global photographs, and Trichoscan at weeks 9, 12, and 24, and hair measurements were performed at baseline and 12 and 24 weeks after the first session. After 24 weeks, the median relative percentage change (%RC) for all the parameters of hair density was mostly positive. After 12 weeks, the medium hair diameter in frontal area showed a significant increase (%RD = 12.5, with P-value < .05), and after 24 weeks (%RD = 14.6, P-value < .05), the vellus relative change instead showed a decrease, especially in the front and the central area, while for the vertex, the decrease was mainly visible at the end (-6.6%). No adverse events were reported. Platelet-rich plasma injections have a positive therapeutic effect on hair density and hair diameter improvement.

Sections du résumé

BACKGROUND BACKGROUND
Recently, platelet-rich plasma (PRP) injection has been proposed as a potential adjuvant therapy to treat androgenetic alopecia.
AIMS OBJECTIVE
Investigate the efficacy, tolerability, and clinical improvement of PRP for the treatment of female AGA.
PATIENTS/METHODS METHODS
A total of 10 female patients affected by AGA and not responding to treatment with minoxidil and/or oral antiandrogens were enrolled. The clinical improvement was evaluated by pull test, global photographs, and Trichoscan at weeks 9, 12, and 24, and hair measurements were performed at baseline and 12 and 24 weeks after the first session.
RESULTS RESULTS
After 24 weeks, the median relative percentage change (%RC) for all the parameters of hair density was mostly positive. After 12 weeks, the medium hair diameter in frontal area showed a significant increase (%RD = 12.5, with P-value < .05), and after 24 weeks (%RD = 14.6, P-value < .05), the vellus relative change instead showed a decrease, especially in the front and the central area, while for the vertex, the decrease was mainly visible at the end (-6.6%). No adverse events were reported.
CONCLUSION CONCLUSIONS
Platelet-rich plasma injections have a positive therapeutic effect on hair density and hair diameter improvement.

Identifiants

pubmed: 29707872
doi: 10.1111/jocd.12550
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

59-64

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Michela Starace (M)

Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Aurora Alessandrini (A)

Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Carmine D'Acunto (C)

Department of Emergency, Burns Center and Dermatology, M Bufalini Hospital, Cesena, Italy.

Davide Melandri (D)

Department of Emergency, Burns Center and Dermatology, M Bufalini Hospital, Cesena, Italy.

Francesca Bruni (F)

Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Annalisa Patrizi (A)

Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Bianca Maria Piraccini (BM)

Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH